$OTLC SEC Filings

Filed On	Filing
26 Oct 2026	8-K: Other Events On October 22, 2026, Saran Saund, Chief Business Officer of Oncotelic Therapeutics Inc. made a presentation at the 22nd Drug Discovery Strategic Summit, October 21–22, 2026 at the Westin San Francisco Airport, Millbrae, California. The p...
13 Oct 2026	8-K: Other Events On October 7 and 8, 2026, representatives of Oncotelic Therapeutics Inc. (the “Company”) presented information regarding its PDAOAI platform and hepatocellular carcinoma (“HCC”) research at Drug Discovery 2026 in Burlingame, California. ...
13 Aug 2026	10-Q
04 Aug 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
23 Jul 2026	Form 4: Fein Seymour Howard, CRO/CMO Granted 250 Restricted stock Units
22 Jul 2026	D
21 Jul 2026	Form 4: King Steven W, Director Granted 250 Restricted stock Units
14 Jul 2026	Form 4: Maida Anthony E Iii, Director Granted 1,500 Restricted stock Units
14 Jul 2026	Form 4: Saund Saran, CBO Granted 1,500 Restricted stock Units
14 Jul 2026	Form 4: Shah Amit B., CFO Granted 1,500 Restricted stock Units
14 Jul 2026	Form 4: Trieu Vuong, Director Granted 2,000 Restricted stock Units
14 Jul 2026	8-K: Other Events
14 Jul 2026	8-K: Unregistered Sales of Equity Securities; Departure/Election of Directors or Officers; Compensation
02 Jul 2026	Form 4: Trieu Vuong, Director Bought 240,000 shares ($10.3K)
29 Jun 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
24 Jun 2026	Form 4: Trieu Vuong, Director Bought 65,000 shares ($2.93K) · Bought 75,000 shares ($3.38K) · Bought 115,000 shares ($5.18K)
22 Jun 2026	Form 4: Shah Amit B., CFO Bought 20,000 shares ($1K)
17 Jun 2026	Form 4: Trieu Vuong, Director Bought 96,000 shares ($4.32K) · Bought 239,759 shares ($10.7K)
14 May 2026	10-Q
05 May 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

Comments